TN2011000364A1 - Methods for treating acute myocardial infarctions and associated disorders - Google Patents
Methods for treating acute myocardial infarctions and associated disordersInfo
- Publication number
- TN2011000364A1 TN2011000364A1 TN2011000364A TN2011000364A TN2011000364A1 TN 2011000364 A1 TN2011000364 A1 TN 2011000364A1 TN 2011000364 A TN2011000364 A TN 2011000364A TN 2011000364 A TN2011000364 A TN 2011000364A TN 2011000364 A1 TN2011000364 A1 TN 2011000364A1
- Authority
- TN
- Tunisia
- Prior art keywords
- methods
- acute myocardial
- associated disorders
- treating acute
- myocardial infarctions
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4433—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with oxygen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4436—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US14734009P | 2009-01-26 | 2009-01-26 | |
PCT/US2010/022112 WO2010085805A1 (fr) | 2009-01-26 | 2010-01-26 | Méthodes de traitement d'infarctus du myocarde aigus et troubles associés |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2011000364A1 true TN2011000364A1 (en) | 2013-03-27 |
Family
ID=42354646
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TN2011000364A TN2011000364A1 (en) | 2009-01-26 | 2011-07-22 | Methods for treating acute myocardial infarctions and associated disorders |
Country Status (16)
Country | Link |
---|---|
US (2) | US20100190731A1 (fr) |
EP (1) | EP2389227A4 (fr) |
JP (1) | JP2012515800A (fr) |
KR (1) | KR20110114684A (fr) |
CN (1) | CN102292124A (fr) |
AP (1) | AP2011005824A0 (fr) |
AU (1) | AU2010206543A1 (fr) |
BR (1) | BRPI1006979A2 (fr) |
CA (1) | CA2747251A1 (fr) |
CL (1) | CL2011001811A1 (fr) |
IL (1) | IL213526A0 (fr) |
MX (1) | MX2011007854A (fr) |
NI (1) | NI201100147A (fr) |
SG (1) | SG172981A1 (fr) |
TN (1) | TN2011000364A1 (fr) |
WO (1) | WO2010085805A1 (fr) |
Families Citing this family (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NZ599643A (en) | 2007-06-20 | 2013-11-29 | Auspex Pharmaceuticals Inc | Substituted N-aryl pyridinones as fibrotic inhibitors |
CA2726588C (fr) | 2008-06-03 | 2019-04-16 | Karl Kossen | Composes et procedes de traitement des troubles inflammatoires et fibrotiques |
KR101478133B1 (ko) | 2009-05-25 | 2014-12-31 | 센트럴 사우스 유니버시티 | 1-(치환된 벤질기)-5-트리플루오로메틸-2-(1h)피리돈 화합물 및 그 염의 제조방법 및 용도 |
CN102149682B (zh) | 2009-05-25 | 2012-12-05 | 中南大学 | 1-(取代芳基)-5-三氟甲基-2-(1h)吡啶酮化合物及其盐的制备方法及其用途 |
BR112013004850B1 (pt) * | 2010-09-01 | 2020-04-07 | Genzyme Corp | uso de um antagonista do tgf-b na preparação de um medicamento para tratamento de infarto do miocárdio |
US10105356B2 (en) | 2011-01-31 | 2018-10-23 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
US10092552B2 (en) | 2011-01-31 | 2018-10-09 | Avalyn Pharma Inc. | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
CN103561741A (zh) | 2011-03-08 | 2014-02-05 | 奥斯拜客斯制药有限公司 | 取代的n-芳基吡啶酮 |
FI20115234A0 (fi) | 2011-03-08 | 2011-03-08 | Biotie Therapies Corp | Uusia pyridatsinoni- ja pyridoniyhdisteitä |
US20150164874A1 (en) * | 2011-05-25 | 2015-06-18 | Intermune, Inc. | Pirfenidone and anti-fibrotic therapy in selected patients |
EP2783016A1 (fr) | 2011-11-22 | 2014-10-01 | Intermune, Inc. | Procédés de diagnostic et de traitement de la fibrose pulmonaire idiopathique |
US9078918B2 (en) * | 2012-05-08 | 2015-07-14 | Northwestern University | Inhibition of fibrosis and AF by TGF-beta inhibition in the posterior left atrium (PLA) |
US9149200B2 (en) * | 2012-05-08 | 2015-10-06 | Northwestern University | Using intracardiac electrograms to predict location of fibrosis and autonomic nerves in the heart |
JP6186434B2 (ja) * | 2012-07-18 | 2017-08-23 | サンシャイン・レイク・ファーマ・カンパニー・リミテッドSunshine Lake Pharma Co.,Ltd. | 窒素複素環誘導体及びその医薬品への応用 |
AR092742A1 (es) | 2012-10-02 | 2015-04-29 | Intermune Inc | Piridinonas antifibroticas |
EP2968292A4 (fr) * | 2013-03-15 | 2016-11-23 | Intermune Inc | Méthodes d'amélioration de l'intégrité microvasculaire |
ES2663806T3 (es) | 2013-12-19 | 2018-04-17 | unshine Lake Pharma Co., Ltd. | Derivados heterocíclicos nitrogenados y su aplicación en el tratamiento de la fibrosis tisular |
NZ722927A (en) | 2014-01-10 | 2022-07-29 | Avalyn Pharma Inc | Aerosol pirfenidone and pyridone analog compounds and uses thereof |
WO2015153683A1 (fr) | 2014-04-02 | 2015-10-08 | Intermune, Inc. | Pyridinones anti-fibrotiques |
EP3307775A4 (fr) * | 2015-06-15 | 2018-12-05 | The Board of Trustees of The Leland Stanford Junior University | Méthodes de diagnostic et de traitement de troubles affectifs |
CN105085383B (zh) * | 2015-08-19 | 2017-09-01 | 四川大学 | 5‑甲基‑2(1h)吡啶酮衍生物及其制备方法和用途 |
CN105669562A (zh) * | 2016-04-05 | 2016-06-15 | 叶芳 | 一种氟取代嘧啶类化合物及其制备方法 |
RU2738844C2 (ru) * | 2016-04-14 | 2020-12-17 | Гуанчжоу Джойо Фарматек Ко., Лтд | Содержащее заместитель, представляющий собой бутан, в гетероциклическом кольце производное пиридона для лечения фиброза и воспалительных заболеваний |
CN107556234A (zh) * | 2016-06-30 | 2018-01-09 | 陕西合成药业股份有限公司 | 一种新型吡啶酮类化合物及其制备方法和在医学上的应用 |
EP3569249A4 (fr) * | 2016-12-27 | 2020-11-11 | Osaka University | Composition pharmaceutique pour traitement de cardiopathie réfractaire |
JP2020516672A (ja) * | 2017-04-18 | 2020-06-11 | セルジーン クオンティセル リサーチ,インク. | 治療用化合物 |
CN107641098A (zh) * | 2017-09-06 | 2018-01-30 | 南阳师范学院 | 一种实现吡啶酮c6位烯基化的方法 |
CA3090270A1 (fr) * | 2018-02-02 | 2019-08-08 | Genentech, Inc. | Compose pharmaceutique, sels de celui-ci, formulations de celui-ci, et procedes de fabrication et d'utilisation de celui-ci |
US20210261672A1 (en) * | 2018-06-22 | 2021-08-26 | Shire Human Genetic Therapies, Inc. | Anti-flt-1 antibodies in treating bronchopulmonary dysplasia |
Family Cites Families (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1049411A (fr) * | 1972-12-18 | 1979-02-27 | Affiliated Medical Research | Pyridone n-substituee; methode generale de synthese des pyridones |
US5518729A (en) * | 1989-11-22 | 1996-05-21 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5310562A (en) * | 1989-11-22 | 1994-05-10 | Margolin Solomon B | Composition and method for reparation and prevention of fibrotic lesions |
US5716632A (en) * | 1989-11-22 | 1998-02-10 | Margolin; Solomon B. | Compositions and methods for reparation and prevention of fibrotic lesions |
US5591766A (en) * | 1993-12-03 | 1997-01-07 | Cheil Foods & Chemicals, Inc. | Solid oral formulations of pyridone carboxylic acids |
US6114353A (en) * | 1995-03-03 | 2000-09-05 | Margolin; Solomon B. | Compositions and method for treatment of lymphomas, leukemias, and leiomyomas |
US6090822A (en) * | 1995-03-03 | 2000-07-18 | Margolin; Solomon B. | Treatment of cytokine growth factor caused disorders |
US5962478A (en) * | 1995-09-19 | 1999-10-05 | Margolin; Solomon B. | Inhibition of tumor necrosis factor α |
US6294350B1 (en) * | 1997-06-05 | 2001-09-25 | Dalhousie University | Methods for treating fibroproliferative diseases |
AU1226099A (en) * | 1998-09-18 | 2000-04-10 | Mepha Ag | Topical formulation of alkyl-, phenyl-pyridone |
US6956044B1 (en) * | 2000-02-21 | 2005-10-18 | Margolin Solomon B | Compositions and methods for treatment of epilepsy |
EP1455813B1 (fr) * | 2001-12-18 | 2015-07-15 | mondoBIOTECH AG | Interferon gamma dans combinaison avec une puce de diagnostic medical pour une utilisation dans le traitement amélioré la fibrose pulmonaire idiopathique |
US20050101581A1 (en) * | 2002-08-28 | 2005-05-12 | Reading Christopher L. | Therapeutic treatment methods 2 |
WO2004019863A2 (fr) * | 2002-08-28 | 2004-03-11 | Intermune, Inc. | Therapie de combinaison pour le traitement de troubles fibrosants |
JP4542743B2 (ja) * | 2002-12-26 | 2010-09-15 | Kdl株式会社 | ピリドン誘導体の溶液状医薬組成物 |
DE10307650A1 (de) * | 2003-02-21 | 2004-09-02 | Endress + Hauser Gmbh + Co. Kg | Verfahren zum Übertragen von Daten über einen Feldbus der Prozessautomatisierungstechnik |
WO2005013917A2 (fr) * | 2003-02-28 | 2005-02-17 | Intermune, Inc. | Therapie combinee servant a traiter une infection par un alphavirus et une fibrose hepatique |
US20070172446A1 (en) * | 2003-05-16 | 2007-07-26 | Intermune, Inc. | Synthetic chemokine receptor ligands and methods of use thereof |
US20070032457A1 (en) * | 2003-05-16 | 2007-02-08 | Blatt Lawrence M | Combination therapy for cancer treatment |
WO2004103296A2 (fr) * | 2003-05-16 | 2004-12-02 | Intermune, Inc. | Methodes de traitement d'une fibrose pulmonaire idiopathique |
US20080025986A1 (en) * | 2003-06-06 | 2008-01-31 | Ozes Osman N | Methods of Treating Tnf-Mediated Disorders |
US7407973B2 (en) * | 2003-10-24 | 2008-08-05 | Intermune, Inc. | Use of pirfenidone in therapeutic regimens |
CA2545813C (fr) * | 2003-11-14 | 2011-01-04 | Shanghai Genomics, Inc. | Derives de pyridone, et utilisation correspondante |
WO2005067454A2 (fr) * | 2003-12-23 | 2005-07-28 | Valeant Pharmaceuticals North America | Polytherapie pour le traitement de l'infection par le virus de l'hepatite c |
US7235530B2 (en) * | 2004-09-27 | 2007-06-26 | Dyax Corporation | Kallikrein inhibitors and anti-thrombolytic agents and uses thereof |
US20090041778A1 (en) * | 2004-11-22 | 2009-02-12 | Sukhatme Vikas P | Methods And Compositions For The Treatment Of Graft Failure |
EP1861072A2 (fr) * | 2005-03-14 | 2007-12-05 | Massachusetts Institute Of Technology | Nanocellules pour le diagnostic et le traitement de maladies et troubles |
ES2600460T3 (es) * | 2005-05-10 | 2017-02-09 | Intermune, Inc. | Derivados de piridona-2-ona como moduladores del sistema de proteína cinasa activada por estrés |
JP5249028B2 (ja) * | 2005-07-25 | 2013-07-31 | インターミューン・インコーポレーテッド | C型肝炎ウイルス複製の新規大環状阻害剤 |
NZ591443A (en) * | 2005-09-22 | 2013-04-26 | Intermune Inc | Granule formation of pirfenidone and pharmaceutically acceptable excipients |
WO2007053658A1 (fr) * | 2005-10-31 | 2007-05-10 | Intermune, Inc. | Compositions de pirfenidone et d'agonistes du recepteur toll-like et leurs methodes d'utilisation pour stimuler la production du facteur stimulant la colonisation des granulocytes |
WO2007053610A2 (fr) * | 2005-11-01 | 2007-05-10 | The Regents Of The University Of California | Traitement de la fibrillation auriculaire a base de pirfenidone |
US20070203202A1 (en) * | 2005-12-02 | 2007-08-30 | Robinson Cynthia Y | Methods of reducing adverse events associated with pirfenidone therapy |
WO2007075388A2 (fr) * | 2005-12-15 | 2007-07-05 | X-Cell Medical Incorporated | Procédés de traitement et de prévention locaux de troubles cardiaques |
BRPI0709950A2 (pt) * | 2006-04-13 | 2011-08-02 | Actelion Pharmaceuticals Ltd | uso de bosentan na preparação de um medicamento para o tratamento de fibrose pulmonar idiopática em estágio precoce e uso de antagonista do receptor endotelin |
US20080003635A1 (en) * | 2006-06-12 | 2008-01-03 | Intermune, Inc. | High Throughput Collagen Synthesis Assay |
JP5213852B2 (ja) * | 2006-06-15 | 2013-06-19 | シャンハイ ゲノミックス インク | 放射線肺障害の予防及び治療のためのピリドン系誘導体の使用 |
KR20090024834A (ko) * | 2006-07-05 | 2009-03-09 | 인터뮨, 인크. | C형 간염 바이러스 복제의 신규 억제제 |
EP2089047B1 (fr) * | 2006-12-11 | 2012-11-14 | 3D Matrix, Inc. | Compositions et procédés visant à protéger et à régénérer un tissu cardiaque |
US7767700B2 (en) * | 2006-12-18 | 2010-08-03 | Intermune, Inc. | Method of providing pirfenidone therapy to a patient |
US20080287508A1 (en) * | 2007-05-18 | 2008-11-20 | Intermune, Inc. | Altering pharmacokinetics of pirfenidone therapy |
CA2726588C (fr) * | 2008-06-03 | 2019-04-16 | Karl Kossen | Composes et procedes de traitement des troubles inflammatoires et fibrotiques |
US7566729B1 (en) * | 2008-11-10 | 2009-07-28 | Intermune, Inc. | Modifying pirfenidone treatment for patients with atypical liver function |
US7635707B1 (en) * | 2008-11-10 | 2009-12-22 | Intermune, Inc. | Pirfenidone treatment for patients with atypical liver function |
-
2010
- 2010-01-26 CN CN2010800055907A patent/CN102292124A/zh active Pending
- 2010-01-26 MX MX2011007854A patent/MX2011007854A/es not_active Application Discontinuation
- 2010-01-26 US US12/693,906 patent/US20100190731A1/en not_active Abandoned
- 2010-01-26 JP JP2011548228A patent/JP2012515800A/ja not_active Withdrawn
- 2010-01-26 SG SG2011050952A patent/SG172981A1/en unknown
- 2010-01-26 WO PCT/US2010/022112 patent/WO2010085805A1/fr active Application Filing
- 2010-01-26 AP AP2011005824A patent/AP2011005824A0/xx unknown
- 2010-01-26 AU AU2010206543A patent/AU2010206543A1/en not_active Abandoned
- 2010-01-26 EP EP10734007A patent/EP2389227A4/fr not_active Withdrawn
- 2010-01-26 KR KR1020117019794A patent/KR20110114684A/ko not_active Application Discontinuation
- 2010-01-26 CA CA2747251A patent/CA2747251A1/fr not_active Abandoned
- 2010-01-26 BR BRPI1006979A patent/BRPI1006979A2/pt not_active Application Discontinuation
-
2011
- 2011-05-25 US US13/115,697 patent/US20110218515A1/en not_active Abandoned
- 2011-06-13 IL IL213526A patent/IL213526A0/en unknown
- 2011-07-22 TN TN2011000364A patent/TN2011000364A1/fr unknown
- 2011-07-25 NI NI201100147A patent/NI201100147A/es unknown
- 2011-07-26 CL CL2011001811A patent/CL2011001811A1/es unknown
Also Published As
Publication number | Publication date |
---|---|
IL213526A0 (en) | 2011-07-31 |
WO2010085805A1 (fr) | 2010-07-29 |
CN102292124A (zh) | 2011-12-21 |
EP2389227A1 (fr) | 2011-11-30 |
US20100190731A1 (en) | 2010-07-29 |
KR20110114684A (ko) | 2011-10-19 |
AP2011005824A0 (en) | 2011-08-31 |
AU2010206543A1 (en) | 2011-07-07 |
CA2747251A1 (fr) | 2010-07-29 |
SG172981A1 (en) | 2011-08-29 |
BRPI1006979A2 (pt) | 2016-04-12 |
EP2389227A4 (fr) | 2012-08-08 |
CL2011001811A1 (es) | 2011-11-11 |
JP2012515800A (ja) | 2012-07-12 |
MX2011007854A (es) | 2011-08-15 |
US20110218515A1 (en) | 2011-09-08 |
NI201100147A (es) | 2011-11-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2011000364A1 (en) | Methods for treating acute myocardial infarctions and associated disorders | |
MY170713A (en) | Treatment protocol of diabetes type 2 | |
IN2015DN01156A (fr) | ||
UA115231C2 (uk) | Сполуки імідазопіролідинонів | |
IN2014DN09805A (fr) | ||
IN2014DN09782A (fr) | ||
GEP201606532B (en) | Benzamide derivatives for inhibiting the activity of abl1, abl2 and bcr-abl1 | |
NZ709392A (en) | Synergistic bacterial compositions and methods of production and use thereof | |
MX356728B (es) | Combinación farmacéutica para usar en el tratamiento de pacientes que padecen diabetes de tipo 2. | |
IN2014DN09804A (fr) | ||
MX2014013858A (es) | Metodo para tratar un cancer positivo de gd2. | |
MX2015004362A (es) | Derivados de ketamina. | |
MY180581A (en) | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof | |
PH12014501195A1 (en) | Novel 2h-indazoles as ep2, receptor antagonists | |
TN2012000610A1 (en) | Heterocyclic compounds, their preparation and their therapeutic application | |
SG10201805267UA (en) | Piperazine derivatives having multimodal activity against pain | |
MX2016006604A (es) | Derivados de piperidina con actividad multimodal contra el dolor. | |
MX2013002121A (es) | Quinolina-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
TN2013000462A1 (en) | Positive allosteric modulators of nicotinic acetylcholine receptor | |
IN2015KN00449A (fr) | ||
MX356317B (es) | Tratamiento de síntomas asociados a gastroparesia femenina. | |
MX367811B (es) | D-metadona para el tratamiento de síntomas psiquiátricos. | |
MX2016006603A (es) | Compuestos piperidinicos con actividad multimodal contra el dolor. | |
MX2013002956A (es) | Arilsulfonamidas para el tratamiento de enfermedades del sistema nervioso central. |